金山科研平台，产品价格货期咨询微信：jinshanbio Source:Mouse myeloma cell line, NS0-derived Accession #:Q6PI12 N-terminal Sequence Analysis:Glu22 Structure:Disulfide-linked homodimer Purity:>95%, by SDS-PAGE under reducing conditions and visualized by silver stain. Endotoxin Level: Predicted Molecular Mass:70.9 kDa (monomer) SDS-PAGE:85-95 kDa, reducing conditions Activity:Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L‑929 mouse fibroblast cells treated with TRAIL.The ED₅₀ for this effect is typically 25 - 50 ng/mL in the presence of 50 ng/mL of recombinant human (rh)TRAIL or 8-15ng/mL in the presence of 12ng/mLcross-linked rhTRAIL (Catalog # 375-TL and MAB050). Formulation:Lyophilized from a 0.2 µm filtered solution in PBS.See Certificate of Analysis for details. Molecule Information: Osteoprotegerin/TNFRSF11B Aliases: OCIF; TNFRSF11B Entrez Gene IDs: 4982 (Human); 18383 (Mouse) Background: Osteoprotegerin/TNFRSF11B (OPG) View Osteoprotegerin IHC images. Osteoprotegerin (OPG)/osteoclastogenesis inhibitory factor (OCIF) is a member of the TNF receptor superfamily and is now referred to as TNFRSF11B. It is an osteoblast secreted decoy receptor that binds specifically to osteoprotegrin ligand (OPGL/TNFSF11) to inhibit osteoblast maturation. It is also a decoy receptor for TRAIL and inhibits TRAIL-induced apoptosis. Human and mouse OPG share approximately 84% and 94% amino acid sequence identity, respectively, with rat OPG. Natural OPG exists predominantly as disulfide-linked dimers.